

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



美瑞健康国际产业集团  
Meilleure Health International Industry Group

**MEILLEURE HEALTH INTERNATIONAL INDUSTRY GROUP LIMITED**

**美瑞健康國際產業集團有限公司**

*(Incorporated in Bermuda with limited liability)*

**(Stock Code: 2327)**

**SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO  
CONTINUING CONNECTED TRANSACTIONS  
FRAMEWORK AGREEMENT – SUPPLY OF SERVICES AND PRODUCTS**

Reference is made to the announcement of Meilleure Health International Industry Group Limited (the “**Company**”, together with its subsidiaries, collectively the “**Group**”) dated 19 November 2021 (the “**Announcement**”) in relation to the Framework Agreement and the transactions contemplated thereunder. Unless otherwise specified, capitalised terms used herein shall have the same meaning defined in the Announcement.

The Company would like to provide potential investors and Shareholders of the Company with further information in respect of the Framework Agreement and the transactions contemplated thereunder as follows:

**ANNUAL CAPS AND BASIS OF DETERMINATION**

With respect to the basis of determination of the proposed annual caps, the Company wishes to supplement that (i) the estimated demand for the provision and supply of the Health Services and Health Products by the Group to ZXZ Group during the term of the Framework Agreement has taken into account the recent launch of a new line of Health Services in October 2021 under the branding of Jibenfenxi\* (肌本分析), which are comprehensive medical aesthetic services targeting mid-to-high end market with the efficacy of restoring the youthfulness of the facial skin, and the expected launch of a new line of Health Services and Health Products in December 2021 under the branding of Jixiaojian\* (肌小簡), which are a variety of light medical aesthetic services

targeting the young consumer market with a range of skincare products complementing the treatments to achieve optimum results, by the Group which are expected to increase the estimated demand by ZXZ Group for the Health Services and Health Products; and (ii) the buffer of around 10% was for any greater than expected demand for the Health Services and Health Products and for any unanticipated market fluctuations.

## **INTERNAL CONTROL MEASURES**

As disclosed in the Announcement, the relevant personnel of the business department of the Company will conduct regular checks to review and assess that the transactions contemplated under the Framework Agreement are conducted in accordance with the terms of the agreement and will also regularly compare the prices and terms with the market prices or standards of similar transactions to consider whether the prices charged on specific transactions are fair and reasonable and in compliance with the pricing policies set out in the Announcement. The Company wishes to supplement that upon receiving an order from ZXZ Group for the provision of Health Services or the supply of Health Products, the relevant personnel of the business department of the Company will check and compare with the prices and terms for at least the two most recent transactions of similar services and products with Independent Third Parties under normal commercial transaction conditions, to ensure that the prices charged on ZXZ Group are fair and reasonable and in compliance with the pricing policies.

Save as disclosed above, all other information and contents of the Announcement remain unchanged.

By Order of the Board  
**Meilleure Health International Industry Group Limited**  
**Zhou Wen Chuan**  
*Executive Director and Chief Executive Officer*

Hong Kong, 25 November 2021

*As at the date of this announcement, the Board comprises Mr. Zhou Xuzhou, Dr. Zeng Wentao and Ms. Zhou Wen Chuan as executive Directors, Dr. Mao Zhenhua as non-executive Director and Mr. Gao Guanjiang, Professor Chau Chi Wai, Wilton and Mr. Wu Peng as independent non-executive Directors.*

*\* For identification purpose only*